Biotech Values

[DewDiligence]

LPTN—I would wait to see the cash situation at the end of 2Q15 before buying strictly as an asset play. Layoffs can be pretty expensive. Moreover, it's far from clear that the company is going to throw in the towel rather than spend the remaining cash on R&D.